Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2013

Open Access 01-12-2013 | Review

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

Authors: James D Mellor, Michael P Brown, Helen R Irving, John R Zalcberg, Alexander Dobrovic

Published in: Journal of Hematology & Oncology | Issue 1/2013

Login to get access

Abstract

Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism of action of therapeutic monoclonal antibodies (mAbs) such as cetuximab, rituximab and trastuzumab. Fc gamma receptors (FcgR) on human white blood cells are an integral part of the ADCC pathway. Differential response to therapeutic mAbs has been reported to correlate with specific polymorphisms in two of these genes: FCGR2A (H131R) and FCGR3A (V158F). These polymorphisms are associated with differential affinity of the receptors for mAbs. This review critically examines the current evidence for genotyping the corresponding single nucleotide polymorphisms (SNPs) to predict response to mAbs in patients with cancer.
Appendix
Available only for authorised users
Literature
1.
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999, 17 (9): 2639-2648.PubMed
2.
Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G: Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu-Positive Metastatic Breast Cancer. J Clin Oncol. 2008, 26 (11): 1789-1796. 10.1200/JCO.2007.14.8957.CrossRefPubMed
3.
Alderson KL, Sondel PM: Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol. 2011, 2011: 379123-PubMedCentralCrossRefPubMed
4.
Ravetch JV, Bolland S: IgG Fc receptors. Annu Rev Immunol. 2001, 19: 275-290. 10.1146/annurev.immunol.19.1.275.CrossRefPubMed
5.
Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000, 6 (4): 443-446. 10.1038/74704.CrossRefPubMed
6.
Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J: In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003, 101 (3): 949-954. 10.1182/blood-2002-02-0469.CrossRefPubMed
7.
Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J: Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer. 2006, 94 (2): 259-267. 10.1038/sj.bjc.6602930.PubMedCentralCrossRefPubMed
8.
Weiner LM, Surana R, Wang S: Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010, 10 (5): 317-327. 10.1038/nri2744.PubMedCentralCrossRefPubMed
9.
Gessner JE, Heiken H, Tamm A, Schmidt RE: The IgG Fc receptor family. Ann Hematol. 1998, 76 (6): 231-248. 10.1007/s002770050396.CrossRefPubMed
10.
Ravetch JV, Perussia B: Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J Exp Med. 1989, 170 (2): 481-497. 10.1084/jem.170.2.481.CrossRefPubMed
11.
Hannani D, Sistigu A, Kepp O, Galluzzi L, Kroemer G, Zitvogel L: Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J. 2011, 17 (5): 351-358. 10.1097/PPO.0b013e3182325d4d.CrossRefPubMed
12.
Clynes R: Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. Hematol Oncol Clin North Am. 2006, 20 (3): 585-612. 10.1016/j.hoc.2006.02.010.CrossRefPubMed
13.
Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL: Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res. 2007, 13 (17): 5133-5143. 10.1158/1078-0432.CCR-07-0507.CrossRefPubMed
14.
Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, Fisher RI, Kelleher RJ, Bankert RB, Bernstein SH: Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood. 2009, 113 (16): 3809-3812. 10.1182/blood-2008-10-185280.PubMedCentralCrossRefPubMed
15.
Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ: A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol. 1991, 147 (4): 1338-1343.PubMed
16.
Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE, Kimberly RP: A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997, 100 (5): 1059-1070. 10.1172/JCI119616.PubMedCentralCrossRefPubMed
17.
Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M: Fc gammaRIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48 L/R/H phenotype. Blood. 1997, 90 (3): 1109-1114.PubMed
18.
Pander J, Gelderblom H, Antonini NF, Tol J, van Krieken JH, van der Straaten T, Punt CJ, Guchelaar HJ: Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer. 2010, 46 (10): 1829-1834. 10.1016/j.ejca.2010.03.017.CrossRefPubMed
19.
Sondermann P, Huber R, Oosthuizen V, Oosthuizen V, Jacob U: The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature. 2000, 406 (6793): 267-273. 10.1038/35018508.CrossRefPubMed
20.
Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD: The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem. 2001, 276 (19): 16469-16477. 10.1074/jbc.M100350200.CrossRefPubMed
21.
Pillay V, Gan HK, Scott AM: Antibodies in oncology. N Biotechnol. 2011, 28 (5): 518-529. 10.1016/j.nbt.2011.03.021.CrossRefPubMed
22.
Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, Kouno T, Katsumata N, Ando M, Aogi K: FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol. 2011, 22 (6): 1302-1307. 10.1093/annonc/mdq585.CrossRefPubMed
23.
Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey JR, Driga A: Analysis of Fcgamma Receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res. 2012, 18 (12): 3478-3486. 10.1158/1078-0432.CCR-11-2294.CrossRefPubMed
24.
25.
Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G: Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004, 64 (13): 4664-4669. 10.1158/0008-5472.CAN-03-2862.CrossRefPubMed
26.
Ghesquieres H, Cartron G, Seymour JF, Delfau-Larue MH, Offner F, Soubeyran P, Perrot A, Brice P, Bouabdallah R, Sonet A: Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood. 2012, 120 (13): 2650-2657. 10.1182/blood-2012-05-431825.CrossRefPubMed
27.
Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D: Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998, 9 (9): 995-1001. 10.1023/A:1008416911099.CrossRefPubMed
28.
Mishima Y, Terui Y, Mishima Y, Kuniyoshi R, Matsusaka S, Mikuniya M, Kojima K, Hatake K: High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcgammaRllla polymorphism. Int Immunol. 2012, 24 (8): 477-483. 10.1093/intimm/dxs048.CrossRefPubMed
29.
Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002, 99 (3): 754-758. 10.1182/blood.V99.3.754.CrossRefPubMed
30.
Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003, 21 (21): 3940-3947. 10.1200/JCO.2003.05.013.CrossRefPubMed
31.
Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, Leblanc M, Maloney DG, Press OW, Miller TP, Rimsza LM: Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica. 2012, 97 (6): 937-942. 10.3324/haematol.2011.050419.PubMedCentralCrossRefPubMed
32.
Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS: FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006, 108 (8): 2720-2725. 10.1182/blood-2006-01-009480.CrossRefPubMed
33.
Dornan D, Spleiss O, Yeh RF, Duchateau-Nguyen G, Dufour A, Zhi J, Robak T, Moiseev SI, Dmoszynska A, Solal-Celigny P: Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood. 2010, 116 (20): 4212-4222. 10.1182/blood-2010-03-272765.CrossRefPubMed
34.
Weng WK, Negrin RS, Lavori P, Horning SJ: Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2010, 28 (2): 279-284. 10.1200/JCO.2009.25.0274.PubMedCentralCrossRefPubMed
35.
Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, Rossi A, Golay J, Pulsoni A, Foa R, Rambaldi A: FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica. 2007, 92 (8): 1127-1130. 10.3324/haematol.11288.CrossRefPubMed
36.
Prochazka V, Papajik T, Gazdova J, Divoka M, Rozmanova S, Faber E, Raida L, Kucerova L, Langova K, Jarosova M: FcgammaRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy. Neoplasma. 2011, 58 (3): 263-270. 10.4149/neo_2011_03_263.CrossRefPubMed
37.
Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frebourg T, Michel P: Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. 2009, 27 (7): 1122-1129. 10.1200/JCO.2008.18.0463.CrossRefPubMed
38.
Qiu LX, Mao C, Zhang J, Zhu XD, Liao RY, Xue K, Li J, Chen Q: Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. Eur J Cancer. 2010, 46 (15): 2781-2787. 10.1016/j.ejca.2010.05.022.CrossRefPubMed
39.
Rodriguez J, Zarate R, Bandres E, Boni V, Hernandez A, Sola JJ, Honorato B, Bitarte N, Garcia-Foncillas J: Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. Eur J Cancer. 2012, 48 (12): 1774-1780. 10.1016/j.ejca.2012.01.007.CrossRefPubMed
40.
Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008, 359 (17): 1757-1765. 10.1056/NEJMoa0804385.CrossRefPubMed
41.
Etienne-Grimaldi MC, Bennouna J, Formento JL, Douillard JY, Francoual M, Hennebelle I, Chatelut E, Francois E, Faroux R, El Hannani C: Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. Br J Clin Pharmacol. 2012, 73 (5): 776-785. 10.1111/j.1365-2125.2011.04141.x.PubMedCentralCrossRefPubMed
42.
Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007, 25 (24): 3712-3718. 10.1200/JCO.2006.08.8021.CrossRefPubMed
43.
Zhang W, Azuma M, Lurje G, Gordon MA, Yang D, Pohl A, Ning Y, Bohanes P, Gerger A, Winder T: Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer Res. 2010, 30 (10): 4209-4217.PubMed
44.
Dahan L, Norguet E, Etienne-Grimaldi MC, Formento JL, Gasmi M, Nanni I, Gaudart J, Garcia S, Ouafik L, Seitz JF: Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer. 2011, 11: 496-10.1186/1471-2407-11-496.PubMedCentralCrossRefPubMed
45.
Paez D, Pare L, Espinosa I, Salazar J, del Rio E, Barnadas A, Marcuello E, Baiget M: Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?. Cancer Sci. 2010, 101 (9): 2048-2053. 10.1111/j.1349-7006.2010.01621.x.CrossRefPubMed
46.
Hatjiharissi E, Hansen M, Santos DD, Xu L, Leleu X, Dimmock EW, Ho AW, Hunter ZR, Branagan AR, Patterson CJ: Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma. 2007, 7 (4): 286-290. 10.3816/CLM.2007.n.004.CrossRefPubMed
47.
Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M: Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol. 2008, 26 (33): 5489-5491. 10.1200/JCO.2008.19.4118. author reply 5491–5482CrossRefPubMed
48.
Cartron G, Trappe RU, Solal-Celigny P, Hallek M: Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res. 2011, 17 (1): 19-30. 10.1158/1078-0432.CCR-10-1292.CrossRefPubMed
49.
Ferris RL, Jaffee EM, Ferrone S: Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 2010, 28 (28): 4390-4399. 10.1200/JCO.2009.27.6360.PubMedCentralCrossRefPubMed
Metadata
Title
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
Authors
James D Mellor
Michael P Brown
Helen R Irving
John R Zalcberg
Alexander Dobrovic
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2013
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-6-1

Other articles of this Issue 1/2013

Journal of Hematology & Oncology 1/2013 Go to the issue

Short report

Selenium and sulindac are synergistic to inhibit intestinal tumorigenesis in Apc/p21 mice

Research

Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma

Review

Intensity modulated radiotherapy for sinonasal malignancies with a focus on optic pathway preservation

Review

Ibrutinib and novel BTK inhibitors in clinical development

Research

Epigenetic inactivation of the MIR129-2 in hematological malignancies

Review

B-Raf and the inhibitors: from bench to bedside
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits